Overview of the development and current use of CRM(197) conjugate vaccines for pediatric use.
Glycoconjugate vaccines have been proven safe and effective against various diseases in children. Although these vaccines have a history of effectiveness, there are still many unanswered questions to be addressed, including conjugate interference when multiple vaccines are administered at one time, expansion of serotype coverage, effectiveness in special populations, and issues relating to conjugate vaccine use in the developing world. This paper focuses on the use of CRM(197) as a carrier protein, contrasting it to other carrier proteins used in single-antigen pediatric vaccines as well as identifying areas for future study.
Shinefield
Henry R
HR
Henryshinefield@aol.com
D000907:Antibodies, Bacterial / Q000276:immunology; D001426:Bacterial Proteins / Q000276:immunology*; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D018074:Vaccines, Conjugate / Q000276:immunology*
D000907:Antibodies, Bacterial; D001426:Bacterial Proteins; D018074:Vaccines, Conjugate; C028581:CRM197 (non-toxic variant of diphtheria toxin)